Oxford Instruments (OXIG) H1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2027 earnings summary
10 Nov, 2026Executive summary
H1 orders rose 44.3% OCC to £296.0m and revenue grew 9.0% OCC to £201.1m; adjusted operating profit increased 21.5% reported to £30.0m.
Advanced Technologies demand and improving margins support FY27 delivery; FY28 revenue growth expectations were raised to ~20%.
Financial highlights
Adjusted operating margin rose 160 bps reported to 14.9%; adjusted PBT increased 21.7% to £30.9m.
Adjusted diluted EPS from continuing operations increased 29.1% to 42.2p; growth would have been 23.0% excluding the buyback-related share-count reduction.
Free cash flow increased to £19.1m from £0.2m; net cash was £74.8m at H1 FY27 versus £45.1m a year earlier.
Interim dividend increased 7.4% to 5.8p per share.
Outlook and guidance
FY27 expectations remain on track; Advanced Technologies expects high-teens revenue growth and a high-single-digit adjusted operating margin, with FY27 revenue covered by orders.
Advanced Technologies FY28 revenue growth is expected at ~20%, with margins in the 12%–15% medium-term range, assuming lead times remain stable.
Imaging and Analysis expects low-single-digit FY27 revenue growth and broadly steady FY27 margin on an OCC basis, with ~120 bps FX headwind.
Imaging and Analysis H2 revenue is expected to exceed H1 by 25% or more, supported by order-book cover.
Latest events from Oxford Instruments
- Strong order momentum and H2 coverage support confidence in FY27 expectations.OXIG
Q2 2027 TU - Order growth and margin gains in H2 set the stage for accelerated FY27 expansion.OXIG
H2 2026 - Strong order growth and resilient H2 performance support a positive outlook for the next year.OXIG
Q4 2026 TU - Strong order growth and capital actions support full-year profit outlook.OXIG
Q3 2026 TU - Order recovery and cost actions set stage for stronger H2 after a challenging first half.OXIG
H1 2026 - H1 order intake rose 1% OCC, but revenues fell 8% OCC; full-year outlook remains stable.OXIG
H1 2026 TU - Strong 10.4% revenue growth and robust order book drive positive full-year outlook.OXIG
H1 2025 - Record revenue, margin expansion, and NanoScience divestment drive strong outlook.OXIG
H2 2025 - Revenue up 9.8%, margin target above 20%, with strong growth and strategic transformation.OXIG
H2 2024